BioCentury
ARTICLE | Company News

Celgene sales and marketing update

July 11, 2016 7:00 AM UTC

The U.K.’s NICE issued a final appraisal determination (FAD) recommending against the use of Vidaza azacitidine from Celgene to treat patients at least 65 years of age who are not eligible for hemato...